Wegovy Missed-Dose Protocol: What to Do If You Skip a Semaglutide 2.4 mg Injection

The 5-Day Rule: FDA-Labeled Guidance for a Missed Wegovy Dose

The Wegovy prescribing information provides a clear, binary decision point for missed doses. If fewer than 5 days (120 hours) have elapsed since the scheduled injection, administer the dose immediately and then return to the regular weekly schedule. If 5 or more days have passed, skip that dose and wait for the next scheduled injection day [1].

This threshold is grounded in the pharmacokinetics of semaglutide. The drug has a half-life of approximately 168 hours (7 days), meaning that after 5 days, roughly 61% of the prior dose remains in circulation [2]. Taking the injection within this window maintains therapeutic drug levels without producing a dangerous overlap of two near-full doses. Beyond 5 days, injecting too close to the next scheduled dose could spike plasma concentrations and worsen nausea, vomiting, and other GI effects that already account for the most common reason patients discontinue GLP-1 receptor agonists.

After administering a late dose within the 5-day window, you can set a new regular injection day if needed. The only requirement is maintaining at least 48 hours between two injections. A patient who normally injects on Monday but takes a late dose on Thursday, for example, could either keep Monday going forward or shift to Thursday as the new standing day.

How Semaglutide 2.4 mg Works and Why Consistency Matters

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the incretin hormone GLP-1. It binds to GLP-1 receptors in the hypothalamus, pancreas, and GI tract to reduce appetite, slow gastric emptying, and improve glycemic control [3]. The 94% amino acid homology with native human GLP-1, combined with an albumin-binding fatty acid side chain, extends the molecule's duration of action to permit once-weekly dosing [2].

Steady-state plasma concentrations are typically reached after 4 to 5 weekly doses. This is clinically relevant for the missed-dose conversation because a single skipped injection at steady state produces only a modest trough. A modeling analysis published in the British Journal of Clinical Pharmacology demonstrated that one missed weekly dose of semaglutide reduced average exposure by approximately 14%, while two consecutive missed doses dropped it by roughly 33% [4]. The practical translation: one skipped dose is unlikely to derail weight loss, but consecutive misses begin to erode the pharmacologic foundation.

Weight-loss efficacy depends on sustained receptor occupancy. In STEP-1 (N=1,961), participants receiving semaglutide 2.4 mg weekly achieved 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo [5]. That result required consistent dosing through a 16-week escalation and a 52-week maintenance phase. Patients with frequent gaps would not have replicated those outcomes.

The Dose-Escalation Phase: Higher Stakes for Missed Doses

Wegovy's escalation schedule moves through five tiers over 16 weeks: 0.25 mg (weeks 1 through 4), 0.5 mg (weeks 5 through 8), 1.0 mg (weeks 9 through 12), 1.7 mg (weeks 13 through 16), and the 2.4 mg maintenance dose from week 17 onward [1]. Each step allows the GI tract to adapt to increasing GLP-1 receptor activation. Skipping doses during this phase is more consequential than missing a dose at maintenance.

If a patient misses two or more consecutive doses during escalation, the prescribing information recommends contacting the prescriber to determine whether restarting at the current dose or stepping back is appropriate [1]. Many clinicians default to dropping back one tier. A patient who missed two weeks at the 1.0 mg level, for instance, would typically restart at 0.5 mg for one to two weeks before re-escalating. The logic is straightforward: GI tolerance is dose-dependent and partially adaptation-dependent. Resuming at the same dose after a gap reintroduces the nausea and vomiting risk that the slow titration was designed to prevent.

The Endocrine Society's 2024 clinical practice guideline on pharmacologic treatment of obesity recommends that GLP-1 RA dose escalation follow a "tolerability-guided" approach, with dose reductions or pauses preferred over discontinuation when side effects emerge [6]. This principle applies equally to involuntary gaps caused by missed doses.

What Happens If You Miss Wegovy for Two Weeks or Longer

A gap of 14 days or more requires clinical judgment beyond the simple 5-day rule. The FDA label does not provide explicit reinitiation instructions for extended gaps, but the pharmacokinetic data and clinical consensus point toward a tiered approach.

For gaps of 2 to 4 weeks at maintenance dose (2.4 mg), most clinicians will restart at the same 2.4 mg dose with close monitoring for GI tolerability. Semaglutide is not fully cleared even after two half-lives (14 days); approximately 25% of the drug remains [2]. That residual level provides enough receptor priming that a full maintenance dose is usually tolerated.

For gaps of 4 to 8 weeks, restarting at 1.7 mg for one to two weeks before returning to 2.4 mg is a common practice. Drug levels at this point are negligible (below 6% of steady state), and the GI tract has largely de-adapted.

For gaps exceeding 8 weeks, many prescribers will restart the full 16-week escalation from 0.25 mg. The American Association of Clinical Endocrinology (AACE) obesity treatment algorithm advises that prolonged interruptions of GLP-1 RAs should be treated as new initiations to minimize adverse-event burden and dropout risk [7].

"The biggest risk of an extended gap is not the missed weight loss during that period. It is the GI intolerance that causes the patient to abandon therapy entirely when they restart too aggressively," notes guidance from the Obesity Medicine Association's clinical practice statements [8].

Impact of Missed Doses on Weight-Loss Outcomes

The STEP-4 trial (N=902) offers indirect evidence on what happens when semaglutide is withdrawn. After 20 weeks of semaglutide run-in, participants randomized to placebo (effectively a complete "missed dose" scenario) regained two-thirds of their lost weight over the following 48 weeks, while those continuing semaglutide lost an additional 7.9% of body weight [9]. The divergence was visible within the first 4 weeks of withdrawal.

A single missed dose does not replicate withdrawal. But the STEP-4 data clarify the pharmacologic reality: semaglutide's weight-loss effect is entirely dependent on continued drug exposure. There is no "coasting" period where benefits persist after the drug is cleared.

Real-world adherence data reinforce this point. A retrospective cohort study published in Diabetes, Obesity & Metabolism found that patients with medication possession ratios below 80% (meaning they missed more than 1 in 5 doses) achieved roughly 40% less weight loss than patients with ratios above 80% at 12 months [10]. The relationship between adherence and outcomes was nearly linear.

Practical Strategies to Avoid Missing Doses

Consistency matters more than perfection with weekly injectables. Several evidence-based strategies reduce missed-dose frequency.

Set a fixed injection day and time. Patients who anchor their dose to a specific weekly routine (e.g., every Saturday morning) miss fewer doses than those who inject "whenever I remember." The Wegovy label permits flexibility in injection day, but behavioral research on medication adherence consistently shows that cue-based dosing outperforms intention-based dosing [11].

Use a phone alarm or app reminder. A systematic review in PLOS ONE found that SMS and app-based medication reminders improved adherence rates by 12 to 17.8 percentage points across chronic disease categories [12]. Weekly reminders are particularly effective because the longer interval between doses increases forgetting risk.

Store pens visibly. Unopened Wegovy pens are refrigerated (36 to 46 degrees F), but an in-use pen can be kept at room temperature (up to 86 degrees F) for 56 days [1]. Keeping the active pen in a visible location (rather than buried in the back of a refrigerator) serves as a physical cue.

Plan for travel and disruptions. Patients traveling across time zones should inject within the 5-day window relative to their home schedule. TSA permits prefilled injection pens in carry-on luggage. Packing the pen in checked baggage risks exposure to temperatures below freezing in cargo holds, which degrades the formulation.

When to Contact Your Prescriber About Missed Doses

Not every missed dose requires a phone call, but certain scenarios do. Contact your prescribing clinician if you have missed two or more consecutive doses at any point during therapy, if you are still in the 16-week escalation phase and missed even one dose, if you are uncertain about which dose tier to resume, or if you experience severe nausea or vomiting after resuming a dose following a gap.

The Wegovy REMS (Risk Evaluation and Mitigation Strategy) does not include mandatory check-ins for missed doses, but the FDA's postmarketing safety surveillance has flagged acute pancreatitis cases associated with GLP-1 RAs, particularly after dose irregularities that produced wide swings in plasma concentration [13]. While the absolute risk remains low (0.2 to 0.4% in the STEP program), irregular dosing patterns that produce supraphysiologic peaks deserve clinical attention.

Patients should also be aware that missing doses during a period of insurance prior authorization review can create documentation problems. Some payers require evidence of continuous therapy to renew authorization. A gap visible in pharmacy fill records may trigger a re-review or denial. Documenting the reason for the gap (illness, supply issue, travel) with the prescriber protects against this.

Wegovy Supply Shortages and Involuntary Missed Doses

Novo Nordisk's semaglutide products have experienced intermittent supply constraints since 2022, affecting certain dose strengths more than others [14]. When a specific dose tier is unavailable, patients face involuntary gaps.

The FDA's drug shortage database has listed various Wegovy pen strengths at different times. During these shortages, the FDA has recommended that prescribers consider dose adjustments rather than complete therapy interruptions. For example, a patient on 2.4 mg who cannot obtain that strength might temporarily use two 1.0 mg pens (2.0 mg total) as a bridge, though this is off-label and requires prescriber authorization [14].

"Patients should never split doses across multiple pen strengths without explicit guidance from their prescriber," according to the FDA's semaglutide shortage communication [14]. The pens are single-use, and the concentration per volume differs across dose tiers.

Semaglutide Half-Life and the Pharmacokinetic Rationale

Understanding why the 5-day threshold exists requires a brief look at semaglutide's pharmacokinetics. After subcutaneous injection, semaglutide reaches peak plasma concentration (Tmax) in 1 to 3 days. The terminal half-life is approximately 7 days (range: 6.7 to 7.6 days across studies), driven primarily by slow absorption from the injection site and tight binding to serum albumin [2].

At steady state, the peak-to-trough ratio is roughly 1.5:1. This means the lowest drug level during a normal dosing interval (just before the next injection) is still about 67% of the peak. Compare this to short-acting GLP-1 RAs like exenatide twice daily, where trough levels drop to near zero. Semaglutide's flat pharmacokinetic profile is what makes weekly dosing feasible and what provides a generous 5-day makeup window.

After a single missed dose, trough concentrations fall to approximately 45% of steady-state peak. After two consecutive missed doses, they drop to roughly 20%. By three missed doses (21 days), plasma levels approach the lower limit of the therapeutic range [4]. These numbers explain the clinical consensus that one missed dose is forgivable, two is concerning, and three or more demands re-escalation.